Chinese inhibitor drug candidate becomes first to enter phase
Release time：2024-04-30 15:01:01 Source：International Ink news portal
Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
Related articles
- 1 military horse under observation, another to recover fully, British Army says
- Xi Stresses Establishing New Systems for Higher
- PLA Eastern Theater Command launches unprecedented live
- Farmers busy with agricultural activities on Cold Dew across China
- 'The Tortured Poets Department' gets largest streaming week ever
- China sees improvements in logistics flow
- China takes countermeasures against U.S. companies selling arms to Taiwan
- Roll of Japanese chemical warfare unit disclosed
- Sports betting roundup: NBA, NHL playoffs rolling on; NFL rookie of the year odds set
- China sees improvements in logistics flow
- GOP leaders still can't overcome the Kansas governor's veto to enact big tax cuts
- Big on barbecue, Zibo's star shines
- View of Xiong'an New Area
- Xi Focus: Xi Stresses Enhancing Party Leadership over Armed Forces
- Arkansas teacher, 26, is charged with sexually assaulting 15
- Global Digital Economy Conference 2022 held in Beijing
- Chinese embassy issues security alert
- Xi Signs Order to Commend Outstanding Military Units, Individuals
- Mel Gibson sports an arm sling following shoulder injury as he attends a coffee meeting in Malibu
- Silk Road int'l expo pushes for deeper Belt and Road cooperation
Random recommendation
- Copyright © 2024 Powered by Chinese inhibitor drug candidate becomes first to enter phase ,International Ink news portal sitemap